Biotechnology US RNAi therapeutics company Alnylam Pharmaceuticals today announced that zilebesiran (formerly ALN-AGT), an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT), has been awarded an Innovation Passport for the treatment of hypertension by the UK Medicines and Healthcare products Regulatory Agency (MHRA), National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Therapeutics and Toxicology Centre (AWTTC). 8 June 2022